Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II randomized double-blind placebo-controlled trial of sodium piragrel injection in acute ischemic stroke
CTR20180545Phase 2Active
- Sponsor
- Hefei Yigong Pharmaceutical
- Start
- May 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of piragrel sodium in ischemic stroke, cerebral sinovenous thrombosis (CSVT), sponsored by Hefei Yigong Pharmaceutical. Started May 2018; status: active.
02
Drugs
piragrel sodium
03
Conditions
ischemic strokecerebral sinovenous thrombosis (CSVT)
Beyond the preview
Go deeper on CTR20180545.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20180545.